BI 639667

BI 639667 is a potent and selective small molecule antagonist of the human C-C chemokine receptor type 1 (CCR1). It was developed by Boehringer Ingelheim as an oral agent. The compound demonstrates high affinity for CCR1 with an IC50 of approximately 1.8 nM in Ca2+ flux assays and shows good physicochemical and pharmacokinetic properties, including a projected human half-life of about 9–12 hours. Preclinical studies were limited by poor rodent cross-reactivity, so in vivo disease models were not extensively pursued. Clinical development reached Phase I to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers; however, further development was discontinued[1][2][3][4][7].

Other names

compound 19ncompound19ncompound-19n